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Introduction 
Presacral carcinoid tumors are rare entities and are 
known to be less aggressive than carcinoid tumors 
found elsewhere in the gastrointestinal tract. Patients 
are frequently asymptomatic and patients usually do 
not present with carcinoid syndrome even with 
metastatic disease. We report a case of a 6cm 
presacral tumor that was detected incidentally 
during a physical examination and had no clinical 
symptoms. The diagnosis was confirmed 
pre-operatively in a biopsy. The patient went on to 
have a transabdominal excision of the pelvic lesion 
with the final histology of a carcinoid tumor. 
  The tumor was subsequently resected enbloc in 
an open surgery and patient recovered well. 
 
Case report 
 
A 49 year old Indian perimenopausal female first 
presented after the discovery of a mass during a 
physical examination done prior to a routine 
screening papanicolaou (PAP) smear. Her medical 
history includes osteoporosis on Fosamax and a 
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Abstract  
Introduction: Gut derived neuroendocrine tumors (NETs) are a heterogenous group of tumors classified as 
Gastroenteropancreatic (GEP) NETs. These tumors can be found along the gastrointestinal tract from the foregut, mid, to 
the hindgut. They are referred to as carcinoid tumors due to their potential to secrete bioactive hormones. 
Presacral tumors are a subset of GEP NETs that are histologically similar. They are uncommon tumors that are found at the 
presacral space and are often clinically silent with no associated carcinoid syndrome.  
Presentation of Case: We report a case of 49 year old female who was diagnosed with a presacral carcinoid tumor. Her 
initial presentation, investigations that led up to the final diagnosis and management of the tumor are discussed.  
Conclusion: Presacral carcinoid tumors are NETs that are clinically and histologically similar to GEPs arising from the 
colon or rectum. Management of such tumors is often surgical resection of localized disease with a long follow-up of 
surveillance to detect recurrence and metastasis. 
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previous ovarian cystectomy for a benign ovarian 
cyst more than fifteen years ago. Her family history 
is significant for breast cancer, prostate cancer and 
leukemia.  
  She had complaints of vague abdominal 
bloatedness and constipation for many years but had 
no other symptoms of abdominal pain, nausea, 
vomiting, change in bowel habits, per rectal bleed or 
melena. There was no history of loss of appetite or 
weight loss. Physical examination revealed a 
palpable mass on the left adnexa with no cervical 
excitation on bimanual palpation per vaginally. Her 
other system reviews were insignificant. Review of 
other body systems was unremarkable. 
She did not report of symptoms like skin flushing, 
wheezing, dyspnoea or watery diarrhoea, typical of 
the carcinoid syndrome.  
  A pelvic ultrasound showed a retro uterine mass 
measuring 4cm (Figure 1). A computed tomographic 
(CT) scan similarly showed a 4x4cm mass at the left 
presacral space displacing the rectum to the right. 
The rectum and urinary bladder close to the mass 
displayed mural thickening with suggestion of 
invasion. There were no other suspicious lesions or 
lymphadenopathy seen in the gastrointestinal tract 
(Figure 2 A, B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 CT imaging of the presacral tumor. (A) Axial view. (B) Coronal view 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 MRI imaging of the presacral tumor. (A) Saggital view. (B) Axial view 
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Further investigations included an 
oesophagoduodenoscopy and colonoscopy that 
showed antral gastritis and no suspicious colonic 
lesions. Blood tests for tumor markers like CEA, 
alpha-feto protein, CA 125 and CA 19-9 were all 
normal. 
  She had an ultrasound guided biopsy of the pelvic 
lesion and histology of the presacral mass was 
suggestive of a carcinoid tumor. 
  A magnetic resonance imaging (MRI) of the 
pelvis was performed to further characterize the 
pelvic tumor as well as to delineate its relations to 
the other structures within the pelvis. The presacral 
tumor was seen as predominantly solid and located 
posteriorly to the rectum in the presacral region. It 
appeared to be separate from the left ovary with 
vascular supply deriving from the lateral pelvic side 
wall rather than the uterine vessels. There was also 
an enlarged uterus suggestive of adenomyosis and 
multiple Nabothian cysts in the cervical region. The 
tumor was localized with a visible resection plane 
and there were no suggestion of osseous or 
neurogenic involvement. The bladder was not seen 
to be involved with the tumor mass. There was no 
regional lymphadenopathy to suggest nodal spread 
[Fig 3a/b]. 
Her case was discussed at a multidisciplinary 
tumor board during which a decision was made to 
proceed with surgical resection of the pelvic tumor.  
  The patient underwent an open, transabdominal 
surgical resection of the presacral tumor. The 
anterior approach (transabdominally) was taken for 
the resection of the tumor to facilitate an extensive 
local resection. Intraoperative findings confirmed 
that the tumor was non-adherent to the rectum, 
mesorectum, bladder or other gynaecological organs. 
Hence decision was made for no bowel resection 
during the enbloc removal of the presacral tumor. 
Sacrectomy was not performed as there was no 
evidence of posterior invasion of the tumor to its 
bony relations. 
  Frozen section of the pre-sacral tumor was 
performed, which was interpreted as a neoplasm 
with differential diagnosis of tumor arising from 
either epithelial, neuroendocrine, sex cord or stromal 
cells. A THBSO was performed in view of the 
frozen section findings and considering 
adenomyosis of the uterus.  
  Her post-operative recovery in the general ward 
was uneventful. She was discharged on 
post-operative day eight. She recovered well but on 
her first follow-up appointment, she complained of 
fever and abdominal pain. She spiked a temperature 
of 39 Degrees Celcius. However septic workup, 
which included urine and blood cultures, was 
negative and the only abnormality was her raised 
total white counts of 16.9x 109/L (normal range 
8-10x109/L). A CT scan performed on post 
operative day twelve showed a pelvic collection and 
mild left hydronephrosis. She was treated with a 
seven-day course of oral antibiotics – ciprofloxacin 
and recovered well and remained afebrile after 
completion of the medication. A surgical drain left in 
situ was removed on post-operative day 17 after the 
output showed a downward trend.  
 
Histopathological Results 
 
Based on the World Health Organization (WHO) 
classification of neuroendocrine tumors (NETs), the 
final histology of the pelvic tumor confirms the 
diagnosis of a well differentiated 6cm grade 2 
neuroendocrine neoplasm (atypical carcinoid) with a 
mitotic rate of 7 per 10 high power field. The 
resection margin and capsular surface were free of 
tumor. Macroscopic description indicated features of 
a well encapsulated tumor with fleshy cut surface 
and focal cystic and haemorrhagic areas. 
Microscopic examination showed cords and 
trabeculae of neuroendocrine cells, similar to the 
histological characteristics of carcinoids. The 
characteristic “salt-and-pepper” nuclear chromatin 
was seen.  
  The tumor cells were positive for CK20 only and 
CK7 and CDX2 were both negative. 
Immunohistochemistry staining was unable to 
conclude the primary site of the carcinoid tumor. 
The THBSO specimen was negative for malignancy 
with the myometrium showing adenomyosis. Both 
ovaries and tubes had benign cysts and there were 
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nabothian cysts on the cervix, detected on the 
pre-operative scans. 
 
Discussion 
 
Majority of NETs are found in the gastrointestinal 
tract (67%) [1]. These tumors are referred to as 
gastroenteropancreatic (GEP) NETs. GEP NETs are 
most common in the small intestine, followed by the 
rectum and appendix. GEP NETs or carcinoid 
tumors found in the presacral region are rare and to 
our knowledge twenty five cases have been reported 
in the literature [2-12]. Most of these reported cases 
were associated with carcinoid tumors derived from 
tailgut cysts (TGCs).  
  TGCs are persistent remnants of the embryonic 
primitive hindgut. These are multiloculated cysts 
lined by a variety of epithelial types [14]. Malignant 
transformation is possible and there had been reports 
of transformation of tailgut cysts to 
adenocarcinomas [14-16], carcinoid tumors [3-13], 
squamous cell carcinomas [18] and sarcomas [19]. 
  Regardless of association with identifiable TGCs 
or not, presacral carcinoid tumors have been often 
hypothesized to arise from neuroendocrine cells in 
the presacral hindgut rests [5, 13, 27]. Due to the 
similarity in histological patterns of presacral 
carcinoids, it is often associated with carcinoid 
tumors of the rectum [14].  
  Presacral carcinoid tumors are indolent growths 
that usually produce symptoms only as a 
consequence of growth. Patients typically do not 
display signs of carcinoid syndrome. This is similar 
to patients with colonic or rectal carcinoids that tend 
to be clinically silent tumors until they are advanced. 
Most patients would complaint of local mass effects 
like pelvic pain or rectal fullness with or without 
associated constipation or haematochezia. Our 
reported case complained of vague abdominal 
bloatedness for many years and was fairly 
asymptomatic otherwise. Occasionally, the tumor 
mass is detected during routine digital rectal or per 
vaginal examination or detected incidentally on 
imaging.  
  A pelvic ultrasound or CT scan can be performed 
to evaluate a mass discovered on per rectal or 
vaginal examination. CT scans are ideal for 
identifying the primary tumor located at the 
presacral region and hepatic metastases that are 
common in advanced disease. Imaging like a MRI is 
also important in the pre-operative planning stage 
for delineation of the pelvic structures that are in 
close proximity with any retrorectal or pre-sacral 
tumor. It also facilitates the planning of the 
operative approach [20]. 
  Surgical resection is the definitive treatment for 
localized pre-sacral carcinoid tumors. The presacral 
tumor can be approached in three ways: the 
transabdominal, the perineal or the combined 
abdominoperineal approach [21]. Low lying and 
small lesions that do not extend above S3 can be 
approached from a posterior approach via a 
parasacral incision. The other two approaches are 
taken to facilitate the need for any concomitant 
sacrococcygeal resection. 
  In the event a sacrectomy is indicated, patients 
must be counselled adequately regarding potential 
functional sequalae of anal incontinence if the sacral 
nerve roots are sacrificed. In general, the 
preservation of at least unilateral S3 nerve roots 
allows for normal bowel and bladder function post 
sacretomy [22]. Pelvic stability must be ensured to 
avoid stress fractures if adjuvant radiation therapy is 
required or was given to the patient pre-operatively. 
The spinopelvic stability can be maintained by 
preservation of more than half the S1 vertebral body 
or restored with a fusion. Though not common, 
carcinoid tumor spreading to the bone has been 
reported mostly of foregut or midgut origin [23, 24]. 
Common sites of bony metastasis are the axial 
skeleton like the spine, ribs and pelvis [25]. There 
has been one report of a rectal carcinoid tumor 
invading the sacrum requiring partial sacretomy [26]. 
  With reference to current published guidelines in 
the literature [28, 29, 30], there are no separate 
guidelines for the specific management of presacral 
carcinoid tumors. However, treatment strategies for 
gastrointestinal carcinoids are all categorized 
anatomically, implying the common clinical 
behaviour of tumors arising from the same 
embryological origin.  
  Carcinoid tumors arising in the retrorectal/ 
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presacral region are often treated surgically, just like 
rectal carcinoids, with the objective of symptomatic 
treatment and cure. Like all gastrointestinal 
carcinoids, presacral carcinoids can metastasize to 
regional lymph nodes and distant sites. Common 
sites of matestasis include liver, lungs and bone [24]. 
The risk of metastasis increases with primary tumor 
size, nodal status, histologic growth pattern and 
microinvasion and presenting symptoms [23, 31, 32]. 
  Rectal carcinoids are known to be least 
aggressive with 82% of the carcinoids at this 
location being localized tumors with no metastasis 
[31]. The propensity of primary rectal carcinoid 
tumors to metastasize is low with high reported 
5-year survival rate of more than 87% compared to 
30-60% of those originating from the foregut and 
midgut [31,1].  
In our patient, the final histology revealed a well 
differentiated, well circumscribed carcinoid tumor 
with clear resection margins and capsular surface 
clear of tumor cells. There was no involvement of 
the resected reproductive organs. However the 
patient has a grade 2 carcinoid, based on mitotic rate 
and would hence be classified as an intermediate 
grade rectal carcinoid based on the WHO 
classification guidelines. In Fahy’s [33] attempt to 
predict the risk stratification of rectal carcinoids, 
poorer outcome was associated with large tumor size, 
deep invasion, presence of LVI, and increased 
mitotic rate. 
Considering the long-natural history of carcinoid 
tumors and its ability to metastasize, post treatment 
follow-up would require regular imaging like 
triphasic CT scans or MRI of the abdomen and 
pelvis. Our reported case would be followed up 
closely with postoperative imaging for local 
recurrence and distal metastasis.  
  It is also recommended to perform blood and 
urine measurements of circulating peptides and 
amines. Baseline tests should include regular plasma 
chromogranin A (CgA) and 5- hydroxyindoleacetic 
acid (5-HIAA). The recommended follow-up period 
as suggested in the National Comprehensive Cancer 
Network (NCCN) guidelines should be at least 7 
years for midgut carcinoid [28]. The initial 
re-evaluation duration to be 3 to 12 months post 
surgical resection and every 6-12 months thereafter. 
  In summary, presacral carcinoid tumors are rare 
entities but when a case is encountered, the 
management approach should always take the 
course similar to that of any GEP NETs. A 
comprehensive history to outline clinical signs and 
symptoms, clinical examination and family history 
to exclude complex cancer syndromes (eg Multiple 
Endocrine Neoplasm 1, 2) are important. Due to 
their indolent and silent presentation, imaging plays 
an important role in diagnosis and staging.  
  Patients may or may not present with symptoms 
attributable to hormonal hypersecretion in presacral 
carcinoid tumors. Laboratory urine and blood tests 
should be performed routinely to rule out carcinoid 
syndrome and also to provide useful clues to the 
origins of the tumor since about 10% of midgut 
carcinoid tumors are often associated with carcinoid 
syndrome. The incidence is usually lower for 
carcinoid tumors from the foregut and hindgut. 
Tumor markers like CEA, ca 19-9 and ca 125 are 
useful in excluding other types of malignancies like 
adenocarcinoma or squamous carcinoma and should 
be performed during any investigation involving 
carcinoid tumors. Surgical resection is the definitive 
treatment for locoregional disease. 
  
Conclusion 
 
Carcinoid tumors in the presacral region are unusual 
growths. These tumors do not differ clinically or 
histologically from carcinoid tumor of the colon and 
rectum. Hence the approach to management can be 
similar. However presacral compared to hindgut 
carcinoid tumors may be less aggressive and more 
localized with no regional lymph node involvement. 
Hence surgical resection may occasionally not 
require resection of the rectum or surrounding pelvic 
organs. The long term follow-up with clinical 
examination and appropriate imaging is required in 
view of the long natural history of carcinoid tumors. 
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